Cargando…
Loading, please waitCargando…
Loading, please waitCondition × Stem Cells
A physician-led look at where mesenchymal stem cell (MSC) therapy stands for hip osteoarthritis: what the published clinical evidence actually shows, who qualifies and who does not, and how care is delivered under COFEPRIS regulation at our clinic in Cancún, México. No prices are published online — every case is reviewed in a free medical evaluation, then quoted in writing.
Mesenchymal stem cell (MSC) therapy is an investigational, physician-led option for hip osteoarthritis that may reduce pain and improve function in selected patients. Across small studies and systematic reviews — including the 2024 systematic review of ten studies covering 316 patients and the 2024 HSS scoping review — intra-articular MSC injections have shown promise on pain and function scores with an acceptable early safety profile, but randomized controlled trials are still needed before MSCs can be considered an established treatment for hip OA. At Regeneris Therapy in Cancún, México, every case starts with a free medical evaluation; only after that do you receive a personalized written quote.
The condition
Hip osteoarthritis (hip OA) is a chronic, progressive disease of the hip joint in which the articular cartilage covering the femoral head and acetabulum thins and breaks down over time. The synovium, subchondral bone, ligaments, and surrounding muscles are all involved — hip OA is increasingly understood as a whole-joint disease rather than purely a cartilage problem. It is one of the most common causes of chronic groin and lateral hip pain in adults over 50, and a leading reason for total hip replacement worldwide.
What the research shows
Peer-reviewed clinical evidence for MSC therapy in hip osteoarthritis is encouraging but still less mature than the evidence base for knee OA. Most hip-specific studies are small, single-arm or non-randomized, and run for 6–24 months; recent systematic and scoping reviews — published in 2023 and 2024 — agree that intra-articular MSC injections appear safe and show consistent signals on pain and function, but that adequately powered randomized controlled trials are still needed. The notes below summarize the strongest sources we cite and what each does and does not show. None of it guarantees an individual outcome.
A recent narrative review focused specifically on mesenchymal stem cells for hip osteoarthritis. The authors identified six clinical studies; five of the six reported statistically significant improvement in patient-reported outcomes after MSC injection, the two studies that captured imaging endpoints reported positive radiological findings, and no major complications were reported. The review explicitly concludes that small non-randomized studies suggest the procedure is safe and produces a positive clinical response, but that randomized controlled trials are still required before MSCs can be considered established care for hip OA.
Candidacy
MSC therapy for hip osteoarthritis is not a first-line treatment, and it is not a fit for every patient. The lists below describe the general clinical factors that point toward or away from regenerative care for this condition at our clinic in Cancún, México. None of these supersede a physician evaluation — they orient you before one.
Regulation & location
Regeneris Therapy operates as a physician-led regenerative-medicine clinic in Cancún, Quintana Roo, México, under COFEPRIS — México's federal health authority, the regulatory equivalent of the U.S. FDA. That framework defines who may prescribe and deliver stem cell therapy, where cells may be processed, and what advertising claims a clinic may publish about hip osteoarthritis or any other indication.
Our clinic operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 — the federal records that authorize medical operations and regulate any advertising of regenerative therapies in México, including those for hip OA.
How we work
Our model is intentionally medical, not transactional. We do not publish prices online for stem cell therapy, and we do not sell a fixed package for hip OA. Every hip case starts with a structured physician evaluation and ends with a written plan and a personalized quote — so you can make an informed decision before committing.
Share your goals, recent hip X-rays or MRI, prior imaging, surgical history, medications, and any conditions. A Regeneris physician reviews your case — by message or video first if you are traveling from outside Cancún — and answers honestly whether MSC therapy is worth considering for your specific hip OA grade.
We confirm the Kellgren–Lawrence grade, joint-space narrowing pattern, presence of avascular necrosis or dysplasia, and the state of surrounding structures (labrum, abductors). If imaging is incomplete or outdated, we tell you what is needed before any decision is made.
If MSC therapy is appropriate, you receive a written plan describing cell source, image-guided intra-articular delivery into the hip, number of sessions, post-procedure rehabilitation, and the personalized quote — clearly stated, no surprises. You take the document home and decide on your own time.
Honest expectations
We treat this section as the most important on the page. Marketing language in regenerative medicine has historically run ahead of the evidence, especially for joint pain. We are deliberately conservative because honesty is the only defensible position in a YMYL medical field.
FAQ
The questions patients ask us most when considering MSC therapy for hip osteoarthritis at our clinic in Cancún, México.
The honest answer is: sometimes, partially, and not for every hip. Published clinical evidence — including the Entessari 2023 narrative review, the Giorgino 2024 systematic review of ten studies covering 316 patients, and the 2024 HSS scoping review of bone-marrow MSCs in hip OA — supports a consistent signal on pain and function in selected patients, with an acceptable early safety profile. But MSC therapy for hip OA is still classified as investigational, randomized controlled trials are still needed, and outcomes vary by Kellgren–Lawrence grade and individual joint. A Regeneris physician will tell you honestly, after evaluation, whether your specific hip is reasonable to treat this way.
This page is informational and does not constitute medical advice. Mesenchymal stem cell therapy for hip osteoarthritis is investigational; outcomes vary by patient, Kellgren–Lawrence grade, and protocol, and no individual response is guaranteed. The decision to pursue MSC therapy is a medical decision that requires an individualized evaluation with a licensed physician; disclose all current medications and conditions. Regeneris Therapy operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 in Cancún, México.
Book a free 15-min call with our team.
Send your goals, recent hip X-rays or MRI, and any prior surgery notes. A Regeneris physician will review your case from Cancún, México and tell you — honestly — whether MSC therapy is worth considering, what protocol may fit, and what the personalized written quote would look like after your free medical evaluation.
A PRISMA-guided systematic review searched PubMed, Embase, and Cochrane for studies of intra-articular MSC injection in patients with hip OA reporting pain as an outcome. Ten studies covering 316 patients were included; outcomes spanned WOMAC, VAS, NRS pain scores, function scores (HOS-ADL, OHS, FRI, LEFS) and, in some studies, MRI- or radiograph-based assessment of cartilage. The authors concluded that intra-articular MSC infiltrations show promise as an effective and safe therapeutic intervention for managing hip OA, while still calling for larger randomized trials — exactly the stance an honest patient-facing page should adopt.
A scoping review from the Hospital for Special Surgery focused specifically on bone-marrow-derived MSCs (BM-MSCs) in human hip osteoarthritis. Seven studies covering 72 patients met inclusion criteria; the review summarizes signals on pain and function and emphasizes that the human evidence base for BM-MSC in hip OA is still small and methodologically heterogeneous, so its conclusions about efficacy are necessarily provisional. It is one of the most recent and hip-specific syntheses available.
An early clinical series examined three consecutive weekly intra-articular infusions of ex vivo expanded autologous bone-marrow MSCs in patients with articular cartilage defects of the hip. The protocol was reported as safe and clinically effective for restoration of hip function and range of motion in this small group of patients — one of the original signals that helped motivate the more recent hip-OA literature, but explicitly framed as a non-randomized study, not as definitive proof of efficacy.
Mechanistic context that frames the entire hip-OA literature. The field's founding figure reframed MSCs as 'medicinal signaling cells,' arguing their therapeutic benefit comes chiefly from secreted, paracrine factors — exosomes, growth factors, cytokines — rather than from engraftment and cartilage replacement. This is the underlying mechanism most often invoked to explain why an MSC injection can reduce pain and improve function in an osteoarthritic hip without literally rebuilding the joint surface.
Read together, the literature supports a careful, conservative position: MSC therapy is biologically rational for hip osteoarthritis and shows a consistent clinical signal across small studies and recent reviews, but it remains investigational for this indication. Whether it is right for your specific hip is a medical question — confirmed only in evaluation at our clinic in Cancún, México, never assumed from a search query.
Cells used in our protocols are expanded under sterile, COFEPRIS-certified laboratory conditions with donor screening and quality-control testing — a baseline patients and families should expect from any serious clinic offering joint injections of biologics.
Every hip-OA protocol is prescribed and supervised by a licensed Mexican physician at our clinic in Cancún, México. Care is not delegated to non-physician staff, and decisions about whether MSC therapy is appropriate are documented in your written plan.
Patients traveling to Cancún, México from the United States, Canada, or elsewhere often combine evaluation, treatment, and recovery on a single short itinerary; our team helps coordinate the medical side from your first message, including imaging review and pre-arrival screening for hip-OA candidacy.
If you proceed, treatment is delivered at our clinic in Cancún, México under physician supervision, with structured follow-up at defined intervals. We reassess pain, range of motion, and function honestly — including the option to refer you onward to an orthopedic surgeon if total hip arthroplasty becomes the better answer.
This is the same workflow whether you are a Cancún resident, a Mexican patient from another state, or an international patient flying in to our clinic in Cancún, México: free evaluation first, written quote only after we understand your hip.
No — and any clinic that says otherwise is overpromising. Some hips clearly need a total hip arthroplasty (for example, end-stage Kellgren–Lawrence Grade IV with bone-on-bone collapse, severe deformity, or constant rest pain). In other cases — especially Grade II–III hip OA in patients with persistent symptoms despite physical therapy and weight optimization, or patients who want to postpone surgery — MSC therapy may be a reasonable adjunct or temporary alternative to consider. The decision is medical, made after imaging and an evaluation at our clinic in Cancún, México.
For hip OA, the most studied route in the published literature is image-guided intra-articular injection — placing the cell preparation directly into the hip joint under sterile conditions and physician supervision, often using ultrasound or fluoroscopic guidance to confirm needle position inside this deep ball-and-socket joint. Some published protocols use one injection; others use a short series of injections spaced over weeks. Your written plan describes exactly which route and schedule apply to you and why, with no hidden steps.
Onset is gradual, not immediate. Anti-inflammatory effects in the hip can build over several weeks; functional gains in groin pain, walking distance, and internal rotation, when they occur, are typically measured across one to several months. Published hip-OA studies generally report outcomes at 3, 6, 12, and 24 months. We schedule structured follow-up at our clinic in Cancún to assess pain and function honestly over that window — including the option to refer you onward if the response is not what you and your physician hoped for.
In published studies of MSC therapy for hip osteoarthritis, including the studies summarized in the Entessari 2023 review and the Giorgino 2024 systematic review, no major complications have been reported and the early safety profile has been acceptable. Common risks of any intra-articular hip injection — temporary soreness, swelling, very low risk of infection — are reviewed with you in your evaluation. Patients with active malignancy, active infection, pregnancy, or uncontrolled immunosuppression are generally deferred without specialist coordination.
Regeneris does not publish prices online for stem cell therapy. Our model is intentional: free medical evaluation first, then a written plan and a personalized quote that reflect your specific hip OA grade, imaging, prior treatments, and goals. We chose this approach because medicine is not a catalog purchase — a number on a homepage cannot fairly represent the decision you are making about your hip. Your full quote is delivered in writing after evaluation at our clinic in Cancún, México, with no obligation to proceed.
Plain-text question-and-answer pairs in semantic HTML — designed to be easily extracted by AI assistants, search engines, and accessibility tools.
How COFEPRIS regulates regenerative medicine in México, what donor screening looks like, and how to evaluate any clinic claim.